<DOC>
	<DOCNO>NCT00457743</DOCNO>
	<brief_summary>Phase I ; To investigate clinically recommend dose Sunitinib malate ( SU011248 ) follow multiple oral dose first cycle ( 4 consecutive week 2 week rest ) review safety tolerability . Phase II ; To determine objective tumor response safety Sunitinib malate ( SU011248 ) clinically recommend dose .</brief_summary>
	<brief_title>A Phase I/II Study Sunitinib Malate ( SU011248 ) In Patients With Gastrointestinal Stromal Tumor ( GIST )</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients histologicallyconfirmed metastatic unresectable gastrointestinal stromal tumor ( GIST ) . Patients previously treat imatinib mesylate . Patients recover acute toxic effect previous antineoplastic therapy treatment imatinib mesylate . Any tumor therapy gastrointestinal stromal tumor ( GIST ) discontinue less 4 week prior start study treatment . Imatinib mesylate discontinue less 2 week prior start therapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Evaluate RTD Japanese GIST patient</keyword>
</DOC>